FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks

Shares of Syndax Pharmaceuticals (SNDX) plunged in intraday trading Monday after the biopharmaceutical company reported that the Food and Drug Administration (FDA) delayed a decision on approving its experimental treatment for acute leukemia. CEO Says Earlier Trials 'Support Approval' Do you have a news tip for Investopedia reporters? Please email us at The Food and Drug Administration (FDA) delayed its approval for a leukemia drug from Syndax Pharmaceuticals after receiving more information from the compan ...